Biomedicines, Journal Year: 2024, Volume and Issue: 12(10), P. 2377 - 2377
Published: Oct. 17, 2024
Dyslipidemia is a common metabolic complication in patients undergoing peritoneal dialysis (PD) and has traditionally been viewed primarily terms of cardiovascular risk. Current guidelines do not recommend initiating lipid-lowering therapy due to insufficient evidence its benefits on mortality. However, the impact dyslipidemia PD may extend beyond concerns, influencing PD-related outcomes such as ultrafiltration rate, residual kidney function, technique survival, overall This review challenges traditional perspective by discussing dyslipidemia’s potential role complications, which account for observed link between increased all-cause mortality patients. It explores pathophysiology PD, molecular mechanisms linking membrane dysfunction, summarizes clinical supporting this hypothesis. In addition, paper examines therapeutic strategies manage improve function patient outcomes. The calls future research investigate contributor dysfunction develop targeted interventions
Language: Английский